Ziopharm Oncology Scientific Advisor Laurence J. N. Cooper, PhD, MD, Presented Today at Aldevron’s Virtual Breakthrough Spe...
28 Abril 2021 - 3:05PM
Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq:
ZIOP), announced today that Laurence J.N. Cooper, PhD, MD,
Scientific Advisor to the Company, was the inaugural presenter at
Aldevron’s Virtual Breakthrough Speaker Series.
“I am excited to participate in this important
event on behalf of Ziopharm,” said Dr. Cooper. “I always look
forward to engaging with the team at Aldevron for the benefit of
interested scientists, clinicians and others. Aldevron and Ziopharm
share a focused passion on developing innovative therapies for
patients suffering from cancer.”
The presentation was followed by a discussion
with Aldevron’s President of its Nucleic Acids Business Unit,
Michelle Berg, and co-Founder and Chief Scientific Officer, John
Ballantyne. Dr. Ballantyne commented, “It is very fitting that Dr.
Cooper kicked off our Breakthrough Speaker Series. We have worked
closely with the team at Ziopharm for years and look forward to a
continued strong partnership. Ziopharm is a clear leader in the
next generation of cellular therapy companies, and it’s exciting to
learn more about their work and the breakthroughs they are
making.”
Dr. Cooper’s comments focused on the distinctive
advantages of Ziopharm’s suite of T-cell therapies, including its
proprietary non-viral gene transfer system, Sleeping Beauty. The
discussion highlights the significant patient need and commercial
opportunity in both hematological and epithelial solid tumor
cancers.
The pre-recorded session is posted on Aldevron’s
website and can be accessed using this link.
About Ziopharm Oncology,
Inc.Ziopharm is developing non-viral and cytokine-driven
cell and gene therapies that weaponize the body’s immune system to
treat the millions of people globally diagnosed with cancer each
year. With its multiplatform approach, Ziopharm is at the forefront
of immuno-oncology. Ziopharm’s pipeline is built for commercially
scalable, cost effective T-cell receptor T-cell therapies based on
its non-viral Sleeping Beauty gene transfer platform, a
precisely controlled IL-12 gene therapy, and rapidly
manufactured Sleeping Beauty-enabled CD19-specific CAR-T
program. The Company has clinical and strategic collaborations with
the National Cancer Institute, The University of Texas MD
Anderson Cancer Center and Regeneron Pharmaceuticals. For more
information, please visit www.ziopharm.com.
Investor Relations Contact:Adam D. Levy, Ph.D.,
MBAEVP, Investor Relations and Corporate CommunicationsT:
508.552.9255E: alevy@ziopharm.com
Forward-Looking Statements
DisclaimerThis press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts, and in some cases can be identified
by terms such as "may," "will," "could," "expects," "plans,"
"anticipates," and "believes." These statements include, but are
not limited to, statements regarding the Company’s cell therapy
programs and technologies, including its commercial potential.
Although Ziopharm’s management team believes that the expectations
reflected in such forward-looking statements are reasonable,
investors are cautioned that forward-looking information and
statements are subject to various risks and uncertainties, many of
which are difficult to predict and generally beyond the control of
Ziopharm, that could cause actual results and developments to
differ materially from those expressed in, or implied or projected
by, the forward-looking information and statements. These risks and
uncertainties include, among other things, the uncertainties
inherent in research and development; future clinical data and
analysis; the strength and enforceability of Ziopharm’s
intellectual property rights; and competition from other
pharmaceutical and biotechnology companies as well as risk factors
discussed or identified in the public filings with
the Securities and Exchange Commission made by Ziopharm,
including those risks and uncertainties listed in Ziopharm’s Annual
Report on Form 10-K filed by Ziopharm with the Securities and
Exchange Commission. We are providing this information as of the
date of this press release, and Ziopharm does not undertake any
obligation to update or revise the information contained in this
press release whether as a result of new information, future events
or any other reason.
ZIOPHARM Oncology (NASDAQ:ZIOP)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
ZIOPHARM Oncology (NASDAQ:ZIOP)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024